- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00460096
Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency (Kamada API)
Randomized Double-Blind Comparison of an Alpha-1 Proteinase Inhibitor (Kamada API) With a Currently Marketed API Product in Individuals With Alpha-1 Antitrypsin Deficiency
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Alpha-1 Antitrypsin Deficiency, also called Alpha-1-Proteinase Inhibitor (API) deficiency, is a genetic disorder characterized by the production of an abnormal amount of AAT protein and reduced circulating levels of this protein. Subjects with AAT deficiency are at increased risk for developing chronic obstructive pulmonary disease (COPD). It is believed that this is the result of the chronic activity of elastase released by cells continually present in the lungs in low numbers.
This study is a randomized, double-blind comparison of Kamada API, an Alpha-1-Proteinase Inhibitor with a currently marketed API product.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80206
- National Jewish Medical and Research Center
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida School of Medicine
-
-
Texas
-
Tyler, Texas, United States, 75708-3154
- The University of Texas Health Center at Tyler
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent.
- "At-risk" alleles associated with serum AAT < 11 μM including null alleles and deficiency alleles. This must be documented in the subject's history or laboratory tests performed at screening.
- At least 18 years of age.
Evidence of lung disease related to AAT deficiency, identified by at least one of the following:
- FEV1<80% predicted (post BD); or
- Loss of lung function over a one year period of greater than 35ml in FEV1; or
- HRCT evidence of pulmonary emphysema
- For actively treated subjects, agreement to not receive any exogenous API product (i.e. washout) for five weeks prior to first study infusion.
- Use of an effective means of contraception during the 24 weeks of study drug administration (this is applicable to both sexes).
- Subjects on the BAL, bronchial brushing/biopsy group must be on inhaled corticosteroids at a stable dose two weeks prior the first Bronchoscopy and throughout the dosing period up the final bronchoscopy.
Exclusion Criteria:
- Laboratory evidence of severe IgA deficiency (from medical history or by IgA testing at screening of at least 20% of lower range).
- Current smoker or a history of smoking within the past 3 months.
- History of allergy to plasma proteins.
- Participation in another experimental drug or device trial within the past 30 days.
- Evidence of uncontrolled hypertension (systolic ≥180 mm Hg, and/or diastolic ≥ 110 mm Hg on 3 consecutive occasions in the supine position)
- Pulse ≥ 120/min (prior to the 1st infusion).
- Abnormal screening or baseline laboratory measurements that in the opinion of the Investigator would affect subject safety.
- Pregnancy or lactation.
- Current life-threatening malignancy.
- Previous organ transplant recipient.
- History of infection with HCV, HBV and/or HIV 1 or 2, or (at baseline) infection indicated by laboratory measurements obtained at screening.
- Acute respiratory tract infection or COPD exacerbation which required antibiotic and/or systemic steroid treatment within the past 6 weeks. Patient can be re-evaluated for enrollment 6 weeks after an exacerbation.
- Any other condition which in the judgment of the investigator may interfere with the conduct of the study.
- If an adequate home health care agency cannot be established by Centric Health Resources due to a potential subject's geographical location.
Exclusion criteria for subjects entering into the BAL and bronchial biopsy/brushing:
- FEV1 < 45% predicted (post-BD).
- Inability to undergo bronchoscopy.
- Allergy to lidocaine.
- Exacerbation of COPD in the previous 6 weeks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Efficacy
|
Secondary Outcome Measures
Outcome Measure |
---|
Safety
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Robert A Sandhaus, M.D., National Jewish Health
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Kamada API-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alpha 1-Antitrypsin Deficiency
-
University of FloridaAlpha-1 FoundationEnrolling by invitation
-
Thomayer University HospitalMasaryk UniversityRecruiting
-
Grifols Therapeutics LLCCompletedAlpha₁-Antitrypsin DeficiencyUnited States
-
Michael Campos, MDCSL BehringCompletedAlpha 1 Antitrypsin DeficiencyUnited States
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)CompletedAlpha 1 Antitrypsin Deficiency | AATDUnited States
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); N... and other collaboratorsTerminatedLiver Cirrhosis | Alpha-1-antitrypsin DeficiencyUnited States
-
Alnylam PharmaceuticalsTerminatedZZ Type Alpha-1 Antitrypsin Deficiency Liver DiseaseUnited Kingdom
-
Hospices Civils de LyonCompletedChildren With a Deficiency of Alpha-1 AntitrypsinFrance
-
Heidelberg UniversityTerminatedHereditary Emphysema (Alpha 1-antitrypsin Deficiency)Germany
-
Grifols Therapeutics LLCCompletedEmphysema | Alpha 1-antitrypsin Deficiency (AATD)United States
Clinical Trials on Kamada-API
-
Kamada, Ltd.CompletedAlpha-1 Antitrypsin DeficiencyUnited States
-
Coeus Health, LLCCompletedWeight Loss | Health BehaviorUnited States
-
Berg, LLCCompletedSquamous Cell CarcinomaUnited States
-
Berg, LLCCompletedSuperficial Basal Cell CarcinomaUnited States
-
Kamada, Ltd.CompletedEmphysemaUnited Kingdom, Canada, Denmark, Germany, Ireland, Netherlands, Sweden
-
Medicines for Malaria VentureCompletedHealthy Volunteers | Malaria Falciparum | Malaria VivaxUnited States
-
Berg, LLCWithdrawn
-
GlaxoSmithKlineCompletedHeart Failure, CongestiveUnited States
-
Kamada, Ltd.Completed
-
Affinium Pharmaceuticals, LtdCompletedCellulitis | Wound Infection | Skin and Subcutaneous Tissue Bacterial Infections | Cutaneous Abscess | Burn InfectionUnited States, Canada